HBSP (USA)
-
The Deutsche Bank (A)
Moss, David A.Case HBS-708044-EFinanceFounded in 1870 to help finance surging German exports and imports, the Deutsche Bank soon moved into domestic banking. In fact, its founders aimed to create both a commercial bank and an investment bank under one roof--that is, a "universal bank." By the end of the nineteenth century, the Deutsche Bank was not only the largest bank in Germany, but also a strategic actor in the broader European market and, indeed, in the world economy. Over the f...Starting at €8.20
-
Unemployment in France: "Priority Number One" (Spanish Version)
Moss, David A.Case HBS-707S28EconomicsExplores the problem of French unemployment on the eve of the presidential elections of 1995. Traces the development of social and economic policies under President Mitterrand and surveys leading explanations for the nation's mounting unemployment crisis. One major theme concerns possible contradictions between France's commitment to European integration and its commitment to expansive social protection for French citizens. Another important them...Starting at €8.20
-
Danatbank
Moss, David A.; Bolton, Cole; Novo, AndrewCase HBS-710059-EEconomicsIn the summer of 1931, Germany was struggling with a deepening economic crisis. Production had fallen, unemployment was high, and bank deposits and gold were being withdrawn from the country at a rapid pace, threatening the value of the German mark. The country's third largest bank, the Danatbank, was especially hard hit by the flagging economy and the flight of capital. By July, the Danatbank was on the verge of collapse, and the bank's charisma...Starting at €8.20
-
Building an Integrated Biopharma Company: Crucell (A)
Hamermesh, Richard G.; Van Der Steen, Marianne; Harmeling, Susan S.Case HBS-815085-EEntrepreneurshipBy 2009, Crucell had become the largest biopharma company in the Netherlands and a symbol of national pride. The case traces the evolution of the company from a University spin-off into a fully-integrated company. Crucell's success, particularly in the vaccine space, had begun to attract the attention of much larger pharmaceutical companies. While there was much appeal to working with these companies, these relationships could also challenge Cruc...Starting at €8.20
-
Building an Integrated Biopharma Company: Crucell (B)
Hamermesh, Richard G.; Van Der Steen, Marianne; Harmeling, Susan S.Case HBS-815086-EEntrepreneurshipThe Crucell (B) case updates events at Crucell since 2009. In September, 2009, Johnson & Johnson acquired 18% of Crucell for $400 million. This investment was part of a business development deal. Subsequently, in 2012, Johnson & Johnson acquired Crucell for $2.8 billion.Starting at €5.74